KLOW 80 mg Research Blend
A 50/10/10/10 blend sold with TB-500 wording. Its batch report should be checked for the exact thymosin form.
Whole vial: 80 mg Vial math ↓
Why people look it up
KLOW combines four talked-about ingredients, so it appears in skin, recovery, and inflammation conversations.
Skin appearance from the blendINSUFFICIENT EVIDENCE
Small topical GHK-Cu work cannot establish effects of the four-ingredient vial. Read source ↗
Recovery from the blendINSUFFICIENT EVIDENCE
Animal BPC-157 results do not test this blend in people. Read source ↗
Gut or inflammation relief from the blendINSUFFICIENT EVIDENCE
Mouse KPV colitis experiments do not establish a benefit from this mixture. Read source ↗
The labels show the evidence for each claim. Open a row for its source.
Dosage at a glance
Dosage source summary
- Lower example
- 2 mg total
- Middle example
- 4 mg total
- Higher example
- 6 mg total
- How often
- Once daily in the published example
- Time on / time off
- The chart does not establish an agreed break schedule.
- Route
- Subcutaneous in that chart
Whole-blend totals calculated by adding the source’s listed ingredients at a 50/10/10/10 ratio. They are not amounts of each ingredient.
These source amounts do not establish a safe human dose for a research vial.
Sources & individual reports
- PeptideDosages published chart; reviewed October 18, 2026
Whole-blend totals calculated by adding the source’s listed ingredients at a 50/10/10/10 ratio. They are not amounts of each ingredient. Source check: 2026-10-18.
Source coverage: 2 reviewed public accounts. Separate examples, not a representative sample.
Report 1 ↗First-person account
- Amount reported
- 8 mg total blend each time: 5 mg GHK-Cu and 1 mg each of three 10 mg ingredients by the stated 50/10/10/10 ratio
- How often reported
- Monday through Friday; weekends off
- Reported duration / cycle
- still using at later follow-up; exact cycle not stated
- Route (how it was taken)
- injection; precise route not stated
What the account says: Poster described a 50/10/10/10 KLOW vial, 20 U from 2 mL, and a five-day weekly pattern. Subjective hair and nail changes were not independently checked.
Product match & source details
Product match: Matches the stated ingredient amounts; thymosin form was written only as TB and cannot be matched to the seller batch.
r/Peptidesource firsthand KLOW comment · Posted: date not independently verified · Reviewed: 2026-10-03.
Report 2 ↗First-person account
- Amount reported
- 2.5 mg GHK-Cu plus 0.5 mg each BPC-157, TB-500 and KPV per stated 10 U
- How often reported
- not stated
- Reported duration / cycle
- not stated
- Route (how it was taken)
- injection implied; route not stated
What the account says: Commenter described a 50/10/10/10 KLOW vial and the amount in a 10 U draw, but did not state how often it was used.
Product match & source details
Product match: Named thymosin as TB-500; seller batch wording has also used TB-4, so molecular identity is not verified.
r/Peptidesource firsthand KLOW comment · Posted: date not independently verified · Reviewed: 2026-10-03.
How much agreement is there? Two accounts describe a 50/10/10/10 ratio, but the thymosin identity remains unclear and the schedules differ or are unstated. No reliable range is established.
Public sources last reviewed: 2026-10-03. Product identity and reported results were not independently verified. Source method →
Evidence, sources & vial math
What the research actually showsHuman studies, evidence limits and mechanisms
What has actually been studied?
No controlled human outcome study of the specific 80 mg blend is established here. Ingredient-specific studies cannot prove the mixture's benefits or safety.
Evidence limits: The finished blend has no independently checked human outcome or regimen here. Ingredient studies cannot validate the combination.
Product status: Research-vial listings are not FDA-approved medicines. Approved-use labels on this page refer only to the named finished prescription product.
Human research
No directly administered human outcome study of this exact four-ingredient KLOW blend was identified among the reviewed ingredient studies and product documentation. The TB-4/TB-500 naming conflict also prevents assuming that research on one thymosin form applies to the other.
Reviewed cited studies and the linked product or regulator documentation; absence of an extracted trial is not proof that no study exists.
Study and prescription-product amounts describe those sources. They do not select an amount for an online research vial.
How researchers think it might work
KLOW combines four separately discussed ingredients. No combined biological mechanism has been established for this exact mixture.
Show scientific explanation
The seller lists GHK-Cu, BPC-157, a thymosin-related component and KPV. Its documentation has used TB-500 and TB-4 terminology; those names can refer to different molecules. Ingredient studies cannot establish a mechanism or benefit for the whole blend. Read supporting source ↗
Vial & syringe mathTurn the vial total and liquid volume into concentration and syringe units
Vial & syringe math
Change the vial total and final liquid volume to see what each U-100 syringe mark represents.
The starting 1 mL is a math example. Enter your final mixed volume to update the numbers.
100 U-100 syringe units = 1 mL. These results assume the labeled amount is evenly mixed through the final liquid volume.
Continue in the calculator →30-day arithmetic: 80 mg divided into 30 equal parts is 2.67 mg of the whole blend per part. This is not a dosing or stability recommendation. Open the 30-day planner →
About this listingResearch-use-only status, seller names and additional background
A research material is not intended for human use. Its name or lab report does not establish suitability for a person. What research use only means →
Compiled by PeptideWhy · Scientific sources last checked 2026-10-03 · Editorial policy · Corrections